Atorvastatin/losartan - HanAll Biopharma

Drug Profile

Atorvastatin/losartan - HanAll Biopharma

Alternative Names: HL-040; HL-040XC; Immediate release atorvastatin/delayed release losartan potassium - HanAll Biopharma; Losartan potassium/atorvastatin Ca - HanAll Biopharma; YH-IMD1

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HanAll Biopharma
  • Developer HanAll Biopharma; Yuhan
  • Class Amides; Antihyperlipidaemics; Antihypertensives; Biphenyl compounds; Fatty acids; Fluorobenzenes; Heart failure therapies; Heptanoic acids; Imidazoles; Ischaemic heart disorder therapies; Pyrroles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Hyperlipidaemia; Hypertension

Most Recent Events

  • 16 Oct 2017 Chemical structure information added
  • 10 Aug 2015 Phase-II development is ongoing in USA
  • 10 Aug 2015 Preregistration for Hyperlipidaemia in South Korea (PO) before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top